Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

Benzinga · 2d ago
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.